{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:27:48Z","timestamp":1791332868275,"version":"4.3.1"},"reference-count":16,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,8,30]],"date-time":"2015-08-30T00:00:00Z","timestamp":1440892800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["journal-of-hepatology.eu","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1016\/j.jhep.2015.07.041","type":"journal-article","created":{"date-parts":[[2015,8,30]],"date-time":"2015-08-30T01:09:49Z","timestamp":1440896989000},"page":"234-238","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":83,"title":["Liver toxicity associated with sofosbuvir, an NS5A inhibitor and ribavirin use"],"prefix":"10.1016","volume":"64","author":[{"given":"Jessica K.","family":"Dyson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Hutchinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olorunda","family":"Rotimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dina","family":"Tiniakos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham R.","family":"Foster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Aldersley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart","family":"McPherson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2015.07.041_b0005","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1056\/NEJMoa1316366","article-title":"Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection","volume":"370","author":"Afdhal","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2015.07.041_b0010","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(14)60111-2","article-title":"All oral fixed-dose combination sofosbuvir\/ledipasvir with or without ribavirin for 12 or 24 weeks in treatment-experienced genotype 1 HCV-infected patients: the phase 3 ION-2 study","volume":"60","author":"Afdhal","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.07.041_b0015","unstructured":"Flamm S, Everson G, Charlton M, et al. Ledipasvir\/Sofosbuvir with Ribavirin for the Treatment of HCV in Patients with Decompensated Cirrhosis: Preliminary Results of a Prospective, Multicenter Study. American Association for the Study of Liver Diseases (AASLD) Liver Meeting 2014; Abstract 239."},{"key":"10.1016\/j.jhep.2015.07.041_b0020","doi-asserted-by":"crossref","unstructured":"Manns M, Forns X, Samuel D, et al. Ledipasvir\/Sofosbuvir with Ribavirin is Safe and Efficacious in Decompensated and Post Liver Transplantation Patients with HCV Infection: Preliminary Results of the Prospective SOLAR 2 Trial. 2015 International Liver Congress: 50th Annual Meeting of the European Association for the Study of the Liver (EASL) 2015; Abstract G02.","DOI":"10.1016\/S0168-8278(15)30003-9"},{"key":"10.1016\/j.jhep.2015.07.041_b0025","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.mayocp.2013.09.016","article-title":"Drug-induced liver injury","volume":"89","author":"Leise","year":"2014","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jhep.2015.07.041_b0030","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1053\/j.gastro.2013.12.032","article-title":"Pathogenesis of idiosyncratic drug-induced liver injury and clinical perspectives","volume":"146","author":"Fontana","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2015.07.041_b0035","unstructured":"Limited B-MSP. Summary of Product Characteristics: Daklinza. 2014 16 October 2014 cited; Available from: <http:\/\/www.medicines.org.uk\/emc\/medicine\/29129>."},{"key":"10.1016\/j.jhep.2015.07.041_b0040","unstructured":"Gilead Sciences I. Prescribing Information: Harvoni. 2014 October 2014 cited; Available from: <http:\/\/www.gilead.com\/~\/media\/Files\/pdfs\/medicines\/liver-disease\/harvoni\/harvoni_pi.pdf>."},{"key":"10.1016\/j.jhep.2015.07.041_b0050","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/ng.379","article-title":"HLA-B\u22175701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin","volume":"41","author":"Daly","year":"2009","journal-title":"Nat Genet"},{"key":"10.1016\/j.jhep.2015.07.041_b0055","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.2147\/DDDT.S40310","article-title":"Daclatasvir: potential role in hepatitis C","volume":"7","author":"Lee","year":"2013","journal-title":"Drug Des Dev Ther"},{"key":"10.1016\/j.jhep.2015.07.041_b0060","unstructured":"Gilead Sciences I. Harvoni Data Sheet, 2015 <http:\/\/www.medsafe.govt.nz\/profs\/datasheet\/h\/HarvoniTab.PDF>."},{"key":"10.1016\/j.jhep.2015.07.041_b0065","series-title":"Chapter 33 \u2013 Adverse effects of hormones and hormone antagonists on the liver. Drug-induced liver disease","author":"Chitturi","year":"2013"},{"key":"10.1016\/j.jhep.2015.07.041_b0070","doi-asserted-by":"crossref","first-page":"3037","DOI":"10.1002\/jps.23584","article-title":"An updated review on drug-induced cholestasis: mechanisms and investigation of physicochemical properties and pharmacokinetic parameters","volume":"102","author":"Yang","year":"2013","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.jhep.2015.07.041_b0075","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/S0016-5085(00)70224-1","article-title":"Drug- and estrogen-induced cholestasis through inhibition of the hepatocellular bile salt export pump (Bsep) of rat liver","volume":"118","author":"Stieger","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2015.07.041_b0080","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/j.1365-2796.1993.tb00745.x","article-title":"Liver damage from low-dose oral contraceptives","volume":"234","author":"Lindgren","year":"1993","journal-title":"J Intern Med"},{"key":"10.1016\/j.jhep.2015.07.041_b0085","unstructured":"Limited A. Summary of Product Characteristics: Exviera. 2015 21 January 2015 cited; Available from: <http:\/\/www.medicines.org.uk\/emc\/medicine\/29785?fromsource=nelm>."}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827815005899?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827815005899?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,30]],"date-time":"2019-08-30T00:40:35Z","timestamp":1567125635000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827815005899"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["S0168827815005899"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2015.07.041","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2016,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Liver toxicity associated with sofosbuvir, an NS5A inhibitor and ribavirin use","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2015.07.041","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2015 European Association for the Study of the Liver. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}